174 related articles for article (PubMed ID: 37804689)
1. Adherence to healthy lifestyle was associated with an attenuation of the risk of chronic kidney disease from metabolic dysfunction-associated fatty liver disease: Results from two prospective cohorts.
Zhang Y; Zhang T; Liu Y; Bai S; Jiang J; Zhou H; Luan J; Cao L; Lv Y; Zhang Q; Liu L; Sun S; Wang X; Zhou M; Jia Q; Song K; Zhang H; Chang Q; Fan X; Ding Y; Chen L; Zhao Y; Niu K; Xia Y
Diabetes Metab Syndr; 2023 Oct; 17(10):102873. PubMed ID: 37804689
[TBL] [Abstract][Full Text] [Related]
2. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study.
Jung CY; Koh HB; Park KH; Joo YS; Kim HW; Ahn SH; Park JT; Kim SU
Diabetes Metab; 2022 Jul; 48(4):101344. PubMed ID: 35346856
[TBL] [Abstract][Full Text] [Related]
3. MAFLD and risk of CKD.
Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
[TBL] [Abstract][Full Text] [Related]
4. The Role of Metabolic Dysfunction-Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study.
Wei S; Song J; Xie Y; Huang J; Yang J
JMIR Public Health Surveill; 2023 May; 9():e45050. PubMed ID: 37140958
[TBL] [Abstract][Full Text] [Related]
5. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W
J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601
[TBL] [Abstract][Full Text] [Related]
6. Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants.
Chen S; Pang J; Huang R; Xue H; Chen X
Hepatol Int; 2023 Jun; 17(3):595-605. PubMed ID: 36809487
[TBL] [Abstract][Full Text] [Related]
7. MAFLD and CKD: An Updated Narrative Review.
Mantovani A; Lombardi R; Cattazzo F; Zusi C; Cappelli D; Dalbeni A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806010
[TBL] [Abstract][Full Text] [Related]
8. The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: A systematic review and meta-analysis.
Agustanti N; Soetedjo NNM; Damara FA; Iryaningrum MR; Permana H; Bestari MB; Supriyadi R
Diabetes Metab Syndr; 2023 May; 17(5):102780. PubMed ID: 37201293
[TBL] [Abstract][Full Text] [Related]
9. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease.
Tanaka M; Mori K; Takahashi S; Higashiura Y; Ohnishi H; Hanawa N; Furuhashi M
Nephrol Dial Transplant; 2023 Feb; 38(3):700-711. PubMed ID: 35612975
[TBL] [Abstract][Full Text] [Related]
10. MAFLD and NAFLD in the prediction of incident chronic kidney disease.
Kwon SY; Park J; Park SH; Lee YB; Kim G; Hur KY; Koh J; Jee JH; Kim JH; Kang M; Jin SM
Sci Rep; 2023 Jan; 13(1):1796. PubMed ID: 36720976
[TBL] [Abstract][Full Text] [Related]
11. Associations between Healthy Lifestyle and All-Cause Mortality in Individuals with Metabolic Associated Fatty Liver Disease.
Wang X; Wang A; Zhang R; Cheng S; Pang Y
Nutrients; 2022 Oct; 14(20):. PubMed ID: 36296904
[TBL] [Abstract][Full Text] [Related]
12. Metabolic associated fatty liver disease is a risk factor for chronic kidney disease.
Hashimoto Y; Hamaguchi M; Okamura T; Nakanishi N; Obora A; Kojima T; Fukui M
J Diabetes Investig; 2022 Feb; 13(2):308-316. PubMed ID: 34561962
[TBL] [Abstract][Full Text] [Related]
13. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
Hu Q; Chen Y; Bao T; Huang Y
Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China.
Wang Y; Yu Y; Zhang H; Chen C; Wan H; Chen Y; Xia F; Yu S; Wang N; Ye L; Lu Y
Front Endocrinol (Lausanne); 2022; 13():968766. PubMed ID: 36120461
[TBL] [Abstract][Full Text] [Related]
15. Coexistence of Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease.
Miyamori D; Tanaka M; Sato T; Endo K; Mori K; Mikami T; Hosaka I; Hanawa N; Ohnishi H; Furuhashi M
J Am Heart Assoc; 2023 Jul; 12(14):e030269. PubMed ID: 37421273
[TBL] [Abstract][Full Text] [Related]
16. Steatotic liver disease, MASLD and risk of chronic kidney disease.
Bilson J; Mantovani A; Byrne CD; Targher G
Diabetes Metab; 2024 Jan; 50(1):101506. PubMed ID: 38141808
[TBL] [Abstract][Full Text] [Related]
17. Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease.
Su W; Chen M; Xiao L; Du S; Xue L; Feng R; Ye W
Front Public Health; 2022; 10():1047794. PubMed ID: 36420005
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome.
Sinn DH; Kang D; Choi SC; Hong YS; Zhao D; Guallar E; Park Y; Cho J; Gwak GY
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1873-1880.e1. PubMed ID: 36152895
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic fatty liver disease without overlapping metabolic-associated fatty liver disease and the risk of incident type 2 diabetes.
Cho Y; Chang Y; Ryu S; Wild SH; Byrne CD
Liver Int; 2023 Nov; 43(11):2445-2454. PubMed ID: 37387519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]